{"name":"Viridian Therapeutics","slug":"viridian-therapeutics","ticker":"VRDN","exchange":"NASDAQ","domain":"viridiantherapeutics.com","description":"Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Walt","hq":"Waltham, MA","founded":0,"employees":"252","ceo":"","sector":"Endocrinology / Ophthalmology","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":17.68,"stockChange":0.64,"stockChangePercent":3.76,"marketCap":"$1.8B","metrics":{"revenue":70918000,"revenueGrowth":95.8,"grossMargin":0,"rdSpend":0,"netIncome":-303267008,"cash":762180992,"dividendYield":0,"peRatio":-6.6,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VRDN-003","genericName":"VRDN-003","slug":"vrdn-003","indication":"Graves' disease (hyperthyroidism)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Veligrotug (VRDN-001)","genericName":"Veligrotug (VRDN-001)","slug":"veligrotug-vrdn-001","indication":"Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk","status":"phase_3"}]}],"pipeline":[{"name":"VRDN-003","genericName":"VRDN-003","slug":"vrdn-003","phase":"phase_3","mechanism":"VRDN-003 is a monoclonal antibody that targets and inhibits thyroid-stimulating immunoglobulin (TSI) to reduce autoimmune thyroid activation in Graves' disease.","indications":["Graves' disease (hyperthyroidism)"],"catalyst":""},{"name":"Veligrotug (VRDN-001)","genericName":"Veligrotug (VRDN-001)","slug":"veligrotug-vrdn-001","phase":"phase_3","mechanism":"Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.","indications":["Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":70849000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":70849000},{"period":"2024-12-31","value":302000},{"period":"2023-12-31","value":314000},{"period":"2022-12-31","value":1772000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":338929000,"rdSpendHistory":[{"period":"2025-12-31","value":338929000},{"period":"2024-12-31","value":238254000},{"period":"2023-12-31","value":159765000},{"period":"2022-12-31","value":100894000}],"sgaSpend":95315000,"operatingIncome":-363395000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-363395000},{"period":"2024-12-31","value":-299035000},{"period":"2023-12-31","value":-254450000},{"period":"2022-12-31","value":-134304000}],"netIncome":-342601000,"netIncomeHistory":[{"period":"2025-12-31","value":-342601000},{"period":"2024-12-31","value":-269949000},{"period":"2023-12-31","value":-237734000},{"period":"2022-12-31","value":-129874000}],"eps":-3.32,"epsHistory":[{"period":"2025-12-31","value":-3.32},{"period":"2024-12-31","value":-3.07},{"period":"2023-12-31","value":-5.31},{"period":"2022-12-31","value":-4.05}],"cash":212382000,"cashHistory":[{"period":"2025-12-31","value":212382000},{"period":"2024-12-31","value":99594000},{"period":"2023-12-31","value":102827000},{"period":"2022-12-31","value":155579000}],"totalAssets":899418000,"totalLiabilities":177251000,"totalDebt":50693000,"equity":722167000,"operatingCashflow":-276391000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-276391000},{"period":"2024-12-31","value":-232319000},{"period":"2023-12-31","value":-184170000},{"period":"2022-12-31","value":-93838000}],"capex":-495000,"capexHistory":[{"period":"2025-12-31","value":-495000},{"period":"2024-12-31","value":-511000},{"period":"2023-12-31","value":-898000},{"period":"2022-12-31","value":-797000}],"freeCashflow":-276886000,"dividendsPaid":null,"buybacks":null,"employees":252,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":33673000,"ebit":-117073000,"ebitda":-116953000,"period":"2025-12-31","revenue":132000,"epsBasic":-1.08,"netIncome":-120355000,"rdExpense":89208000,"epsDiluted":-1.08,"grossProfit":null,"operatingIncome":-122749000},{"sga":24322000,"ebit":-34039000,"ebitda":-33929000,"period":"2025-09-30","revenue":70570000,"epsBasic":-0.34,"netIncome":-34599000,"rdExpense":86261000,"epsDiluted":-0.34,"grossProfit":null,"operatingIncome":-40013000},{"sga":20216000,"ebit":-100221000,"ebitda":-100108000,"period":"2025-06-30","revenue":75000,"epsBasic":-1,"netIncome":-100735000,"rdExpense":86626000,"epsDiluted":-1,"grossProfit":null,"operatingIncome":-106767000},{"sga":17103000,"ebit":-86326000,"ebitda":-86209000,"period":"2025-03-31","revenue":72000,"epsBasic":-0.87,"netIncome":-86912000,"rdExpense":76835000,"epsDiluted":-0.87,"grossProfit":null,"operatingIncome":-93866000},{"sga":15584000,"ebit":-78867000,"ebitda":-78744000,"period":"2024-12-31","revenue":72000,"epsBasic":-0.81,"netIncome":-79725000,"rdExpense":71960000,"epsDiluted":-0.81,"grossProfit":null,"operatingIncome":-87472000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":17.68,"previousClose":17.04,"fiftyTwoWeekHigh":34.29,"fiftyTwoWeekLow":12.13,"fiftyTwoWeekRange":"12.133 - 34.29","fiftyDayAverage":20.15,"twoHundredDayAverage":24.32,"beta":0.82,"enterpriseValue":1179618560,"forwardPE":-6.6,"priceToBook":3.05,"priceToSales":25.7,"enterpriseToRevenue":16.63,"enterpriseToEbitda":-3.06,"pegRatio":0,"ebitda":-385233984,"ebitdaMargin":0,"freeCashflow":-182550752,"operatingCashflow":-303392000,"totalDebt":53350000,"debtToEquity":8.4,"currentRatio":15.15,"returnOnAssets":-33.2,"returnOnEquity":-58.1,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":16,"targetMeanPrice":34.56,"targetHighPrice":50,"targetLowPrice":20,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":104.5,"sharesOutstanding":103074740,"floatShares":97599410,"sharesShort":11512229,"shortRatio":3.37,"shortPercentOfFloat":11.2,"epsTrailing":-3.35,"epsForward":-2.67,"revenuePerShare":0.79,"bookValue":5.79,"officers":[{"age":54,"name":"Mr. Stephen F. Mahoney J.D., MBA","title":"CEO, President & Director"},{"age":44,"name":"Mr. Seth  Harmon","title":"Chief Financial Officer"},{"age":55,"name":"Mr. Thomas W. Beetham J.D., MBA","title":"Chief Operating Officer"},{"age":52,"name":"Ms. Jennifer  Tousignant J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":45,"name":"Dr. Radhika  Tripuraneni M.D., M.P.H.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Eric N. Olson Ph.D.","title":"Co-Founder & Chairman of Scientific Advisory Board"},{"age":80,"name":"Dr. Michael R. Bristow M.D., Ph.D.","title":"Co-Founder & Member of the Scientific Advisory Board"},{"age":85,"name":"Dr. Marvin H. Caruthers Ph.D.","title":"Co-Founder & Scientific Advisory Board Member"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.viridiantherapeutics.com","phone":"617 272 4600"}}